nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—ABCG2—Sulfasalazine—ankylosing spondylitis	0.184	0.21	CbGbCtD
Topotecan—ABCG2—Dexamethasone—ankylosing spondylitis	0.0918	0.105	CbGbCtD
Topotecan—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0875	0.1	CbGbCtD
Topotecan—ABCG2—Methotrexate—ankylosing spondylitis	0.0738	0.0844	CbGbCtD
Topotecan—ABCB1—Betamethasone—ankylosing spondylitis	0.0569	0.0651	CbGbCtD
Topotecan—ABCB1—Prednisolone—ankylosing spondylitis	0.0561	0.0642	CbGbCtD
Topotecan—ABCB1—Prednisone—ankylosing spondylitis	0.053	0.0606	CbGbCtD
Topotecan—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0524	0.06	CbGbCtD
Topotecan—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0397	0.0454	CbGbCtD
Topotecan—CYP3A4—Betamethasone—ankylosing spondylitis	0.0341	0.039	CbGbCtD
Topotecan—CYP3A4—Prednisolone—ankylosing spondylitis	0.0336	0.0385	CbGbCtD
Topotecan—ABCB1—Dexamethasone—ankylosing spondylitis	0.0331	0.0379	CbGbCtD
Topotecan—CYP3A4—Prednisone—ankylosing spondylitis	0.0318	0.0363	CbGbCtD
Topotecan—ABCB1—Methotrexate—ankylosing spondylitis	0.0266	0.0304	CbGbCtD
Topotecan—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0198	0.0227	CbGbCtD
Topotecan—Haemorrhage—Betamethasone—ankylosing spondylitis	0.000464	0.00369	CcSEcCtD
Topotecan—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.000464	0.00369	CcSEcCtD
Topotecan—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000463	0.00368	CcSEcCtD
Topotecan—Immune system disorder—Methylprednisolone—ankylosing spondylitis	0.000461	0.00366	CcSEcCtD
Topotecan—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.00046	0.00366	CcSEcCtD
Topotecan—Weight increased—Prednisone—ankylosing spondylitis	0.00046	0.00365	CcSEcCtD
Topotecan—Ill-defined disorder—Prednisolone—ankylosing spondylitis	0.00045	0.00357	CcSEcCtD
Topotecan—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000445	0.00353	CcSEcCtD
Topotecan—Angioedema—Prednisolone—ankylosing spondylitis	0.000443	0.00352	CcSEcCtD
Topotecan—Neuropathy peripheral—Prednisone—ankylosing spondylitis	0.000442	0.00351	CcSEcCtD
Topotecan—Malaise—Prednisolone—ankylosing spondylitis	0.000437	0.00347	CcSEcCtD
Topotecan—Back pain—Triamcinolone—ankylosing spondylitis	0.000431	0.00342	CcSEcCtD
Topotecan—Angiopathy—Betamethasone—ankylosing spondylitis	0.000421	0.00335	CcSEcCtD
Topotecan—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000421	0.00335	CcSEcCtD
Topotecan—Ill-defined disorder—Triamcinolone—ankylosing spondylitis	0.000413	0.00328	CcSEcCtD
Topotecan—Ill-defined disorder—Methylprednisolone—ankylosing spondylitis	0.000412	0.00328	CcSEcCtD
Topotecan—Alopecia—Dexamethasone—ankylosing spondylitis	0.00041	0.00326	CcSEcCtD
Topotecan—Alopecia—Betamethasone—ankylosing spondylitis	0.00041	0.00326	CcSEcCtD
Topotecan—Discomfort—Prednisolone—ankylosing spondylitis	0.000408	0.00324	CcSEcCtD
Topotecan—Angioedema—Triamcinolone—ankylosing spondylitis	0.000407	0.00323	CcSEcCtD
Topotecan—Haemoglobin—Prednisone—ankylosing spondylitis	0.000406	0.00323	CcSEcCtD
Topotecan—Angioedema—Methylprednisolone—ankylosing spondylitis	0.000406	0.00323	CcSEcCtD
Topotecan—Haemorrhage—Prednisone—ankylosing spondylitis	0.000404	0.00321	CcSEcCtD
Topotecan—Malaise—Triamcinolone—ankylosing spondylitis	0.000402	0.00319	CcSEcCtD
Topotecan—Pancytopenia—Methotrexate—ankylosing spondylitis	0.000401	0.00319	CcSEcCtD
Topotecan—Malaise—Methylprednisolone—ankylosing spondylitis	0.000401	0.00318	CcSEcCtD
Topotecan—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.000395	0.00314	CcSEcCtD
Topotecan—Neutropenia—Methotrexate—ankylosing spondylitis	0.000395	0.00314	CcSEcCtD
Topotecan—Cough—Triamcinolone—ankylosing spondylitis	0.000389	0.00309	CcSEcCtD
Topotecan—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000382	0.00304	CcSEcCtD
Topotecan—Myalgia—Triamcinolone—ankylosing spondylitis	0.000379	0.00301	CcSEcCtD
Topotecan—Pneumonia—Methotrexate—ankylosing spondylitis	0.000379	0.00301	CcSEcCtD
Topotecan—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000378	0.00301	CcSEcCtD
Topotecan—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000378	0.00301	CcSEcCtD
Topotecan—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000377	0.00299	CcSEcCtD
Topotecan—Infestation—Methotrexate—ankylosing spondylitis	0.000377	0.00299	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000376	0.00299	CcSEcCtD
Topotecan—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.000375	0.00298	CcSEcCtD
Topotecan—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.000375	0.00298	CcSEcCtD
Topotecan—Discomfort—Triamcinolone—ankylosing spondylitis	0.000375	0.00298	CcSEcCtD
Topotecan—Discomfort—Methylprednisolone—ankylosing spondylitis	0.000374	0.00297	CcSEcCtD
Topotecan—Angioedema—Betamethasone—ankylosing spondylitis	0.000369	0.00293	CcSEcCtD
Topotecan—Angioedema—Dexamethasone—ankylosing spondylitis	0.000369	0.00293	CcSEcCtD
Topotecan—Stomatitis—Methotrexate—ankylosing spondylitis	0.000367	0.00292	CcSEcCtD
Topotecan—Angiopathy—Prednisone—ankylosing spondylitis	0.000367	0.00291	CcSEcCtD
Topotecan—Immune system disorder—Prednisone—ankylosing spondylitis	0.000365	0.0029	CcSEcCtD
Topotecan—Malaise—Betamethasone—ankylosing spondylitis	0.000365	0.0029	CcSEcCtD
Topotecan—Malaise—Dexamethasone—ankylosing spondylitis	0.000365	0.0029	CcSEcCtD
Topotecan—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000364	0.00289	CcSEcCtD
Topotecan—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000363	0.00288	CcSEcCtD
Topotecan—Infection—Triamcinolone—ankylosing spondylitis	0.000361	0.00287	CcSEcCtD
Topotecan—Sweating—Methotrexate—ankylosing spondylitis	0.000361	0.00287	CcSEcCtD
Topotecan—Infection—Methylprednisolone—ankylosing spondylitis	0.00036	0.00286	CcSEcCtD
Topotecan—Alopecia—Prednisone—ankylosing spondylitis	0.000357	0.00284	CcSEcCtD
Topotecan—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000356	0.00283	CcSEcCtD
Topotecan—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000356	0.00283	CcSEcCtD
Topotecan—Epistaxis—Methotrexate—ankylosing spondylitis	0.000355	0.00282	CcSEcCtD
Topotecan—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000355	0.00282	CcSEcCtD
Topotecan—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000352	0.0028	CcSEcCtD
Topotecan—Malnutrition—Prednisone—ankylosing spondylitis	0.000352	0.0028	CcSEcCtD
Topotecan—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000352	0.00279	CcSEcCtD
Topotecan—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000351	0.00279	CcSEcCtD
Topotecan—Myalgia—Dexamethasone—ankylosing spondylitis	0.000344	0.00273	CcSEcCtD
Topotecan—Myalgia—Betamethasone—ankylosing spondylitis	0.000344	0.00273	CcSEcCtD
Topotecan—Discomfort—Dexamethasone—ankylosing spondylitis	0.00034	0.0027	CcSEcCtD
Topotecan—Discomfort—Betamethasone—ankylosing spondylitis	0.00034	0.0027	CcSEcCtD
Topotecan—Haemoglobin—Methotrexate—ankylosing spondylitis	0.00034	0.0027	CcSEcCtD
Topotecan—Pain—Prednisolone—ankylosing spondylitis	0.000338	0.00269	CcSEcCtD
Topotecan—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000338	0.00268	CcSEcCtD
Topotecan—Pharyngitis—Methotrexate—ankylosing spondylitis	0.000335	0.00266	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000331	0.00263	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000331	0.00263	CcSEcCtD
Topotecan—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.00033	0.00262	CcSEcCtD
Topotecan—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.00033	0.00262	CcSEcCtD
Topotecan—Infection—Dexamethasone—ankylosing spondylitis	0.000328	0.0026	CcSEcCtD
Topotecan—Infection—Betamethasone—ankylosing spondylitis	0.000328	0.0026	CcSEcCtD
Topotecan—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000327	0.00259	CcSEcCtD
Topotecan—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000327	0.00259	CcSEcCtD
Topotecan—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000326	0.00259	CcSEcCtD
Topotecan—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000326	0.00259	CcSEcCtD
Topotecan—Anaemia—Prednisone—ankylosing spondylitis	0.000325	0.00258	CcSEcCtD
Topotecan—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000324	0.00258	CcSEcCtD
Topotecan—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000324	0.00257	CcSEcCtD
Topotecan—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000324	0.00257	CcSEcCtD
Topotecan—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000323	0.00257	CcSEcCtD
Topotecan—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000323	0.00257	CcSEcCtD
Topotecan—Angioedema—Prednisone—ankylosing spondylitis	0.000322	0.00256	CcSEcCtD
Topotecan—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.00032	0.00254	CcSEcCtD
Topotecan—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000319	0.00254	CcSEcCtD
Topotecan—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000319	0.00253	CcSEcCtD
Topotecan—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000319	0.00253	CcSEcCtD
Topotecan—Malaise—Prednisone—ankylosing spondylitis	0.000317	0.00252	CcSEcCtD
Topotecan—Anorexia—Dexamethasone—ankylosing spondylitis	0.000315	0.0025	CcSEcCtD
Topotecan—Anorexia—Betamethasone—ankylosing spondylitis	0.000315	0.0025	CcSEcCtD
Topotecan—Urticaria—Prednisolone—ankylosing spondylitis	0.000314	0.0025	CcSEcCtD
Topotecan—Fatigue—Triamcinolone—ankylosing spondylitis	0.000314	0.00249	CcSEcCtD
Topotecan—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000313	0.00248	CcSEcCtD
Topotecan—Pain—Triamcinolone—ankylosing spondylitis	0.000311	0.00247	CcSEcCtD
Topotecan—Angiopathy—Methotrexate—ankylosing spondylitis	0.000307	0.00244	CcSEcCtD
Topotecan—Immune system disorder—Methotrexate—ankylosing spondylitis	0.000305	0.00243	CcSEcCtD
Topotecan—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000305	0.00242	CcSEcCtD
Topotecan—Chills—Methotrexate—ankylosing spondylitis	0.000303	0.00241	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000301	0.00239	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000301	0.00239	CcSEcCtD
Topotecan—Arthralgia—Prednisone—ankylosing spondylitis	0.0003	0.00238	CcSEcCtD
Topotecan—Myalgia—Prednisone—ankylosing spondylitis	0.0003	0.00238	CcSEcCtD
Topotecan—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.0003	0.00238	CcSEcCtD
Topotecan—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000299	0.00238	CcSEcCtD
Topotecan—Alopecia—Methotrexate—ankylosing spondylitis	0.000299	0.00237	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000298	0.00236	CcSEcCtD
Topotecan—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000297	0.00236	CcSEcCtD
Topotecan—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000296	0.00235	CcSEcCtD
Topotecan—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000296	0.00235	CcSEcCtD
Topotecan—Discomfort—Prednisone—ankylosing spondylitis	0.000296	0.00235	CcSEcCtD
Topotecan—Malnutrition—Methotrexate—ankylosing spondylitis	0.000294	0.00234	CcSEcCtD
Topotecan—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000291	0.00231	CcSEcCtD
Topotecan—Dyspepsia—Betamethasone—ankylosing spondylitis	0.00029	0.00231	CcSEcCtD
Topotecan—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.00029	0.00231	CcSEcCtD
Topotecan—Urticaria—Triamcinolone—ankylosing spondylitis	0.000289	0.00229	CcSEcCtD
Topotecan—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000288	0.00229	CcSEcCtD
Topotecan—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000287	0.00228	CcSEcCtD
Topotecan—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000287	0.00228	CcSEcCtD
Topotecan—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000287	0.00228	CcSEcCtD
Topotecan—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000287	0.00228	CcSEcCtD
Topotecan—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000287	0.00228	CcSEcCtD
Topotecan—Infection—Prednisone—ankylosing spondylitis	0.000285	0.00227	CcSEcCtD
Topotecan—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000285	0.00226	CcSEcCtD
Topotecan—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000285	0.00226	CcSEcCtD
Topotecan—Back pain—Methotrexate—ankylosing spondylitis	0.000285	0.00226	CcSEcCtD
Topotecan—Fatigue—Dexamethasone—ankylosing spondylitis	0.000284	0.00226	CcSEcCtD
Topotecan—Fatigue—Betamethasone—ankylosing spondylitis	0.000284	0.00226	CcSEcCtD
Topotecan—Pain—Betamethasone—ankylosing spondylitis	0.000282	0.00224	CcSEcCtD
Topotecan—Pain—Dexamethasone—ankylosing spondylitis	0.000282	0.00224	CcSEcCtD
Topotecan—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000282	0.00224	CcSEcCtD
Topotecan—Skin disorder—Prednisone—ankylosing spondylitis	0.000279	0.00222	CcSEcCtD
Topotecan—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000278	0.00221	CcSEcCtD
Topotecan—Anorexia—Prednisone—ankylosing spondylitis	0.000274	0.00218	CcSEcCtD
Topotecan—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000273	0.00217	CcSEcCtD
Topotecan—Anaemia—Methotrexate—ankylosing spondylitis	0.000272	0.00216	CcSEcCtD
Topotecan—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000272	0.00216	CcSEcCtD
Topotecan—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000272	0.00216	CcSEcCtD
Topotecan—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.00027	0.00214	CcSEcCtD
Topotecan—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.00027	0.00214	CcSEcCtD
Topotecan—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000268	0.00213	CcSEcCtD
Topotecan—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000267	0.00212	CcSEcCtD
Topotecan—Malaise—Methotrexate—ankylosing spondylitis	0.000265	0.00211	CcSEcCtD
Topotecan—Leukopenia—Methotrexate—ankylosing spondylitis	0.000263	0.00209	CcSEcCtD
Topotecan—Urticaria—Betamethasone—ankylosing spondylitis	0.000262	0.00208	CcSEcCtD
Topotecan—Urticaria—Dexamethasone—ankylosing spondylitis	0.000262	0.00208	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000262	0.00208	CcSEcCtD
Topotecan—Dizziness—Prednisolone—ankylosing spondylitis	0.000261	0.00208	CcSEcCtD
Topotecan—Asthenia—Triamcinolone—ankylosing spondylitis	0.000261	0.00207	CcSEcCtD
Topotecan—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000261	0.00207	CcSEcCtD
Topotecan—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000261	0.00207	CcSEcCtD
Topotecan—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000261	0.00207	CcSEcCtD
Topotecan—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000261	0.00207	CcSEcCtD
Topotecan—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00026	0.00207	CcSEcCtD
Topotecan—Paraesthesia—Prednisone—ankylosing spondylitis	0.000258	0.00205	CcSEcCtD
Topotecan—Pruritus—Triamcinolone—ankylosing spondylitis	0.000257	0.00204	CcSEcCtD
Topotecan—Cough—Methotrexate—ankylosing spondylitis	0.000257	0.00204	CcSEcCtD
Topotecan—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000257	0.00204	CcSEcCtD
Topotecan—Dyspepsia—Prednisone—ankylosing spondylitis	0.000253	0.00201	CcSEcCtD
Topotecan—Myalgia—Methotrexate—ankylosing spondylitis	0.000251	0.00199	CcSEcCtD
Topotecan—Chest pain—Methotrexate—ankylosing spondylitis	0.000251	0.00199	CcSEcCtD
Topotecan—Arthralgia—Methotrexate—ankylosing spondylitis	0.000251	0.00199	CcSEcCtD
Topotecan—Decreased appetite—Prednisone—ankylosing spondylitis	0.00025	0.00198	CcSEcCtD
Topotecan—Rash—Prednisolone—ankylosing spondylitis	0.000249	0.00198	CcSEcCtD
Topotecan—Dermatitis—Prednisolone—ankylosing spondylitis	0.000249	0.00198	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000249	0.00198	CcSEcCtD
Topotecan—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000248	0.00197	CcSEcCtD
Topotecan—Fatigue—Prednisone—ankylosing spondylitis	0.000248	0.00197	CcSEcCtD
Topotecan—Headache—Prednisolone—ankylosing spondylitis	0.000248	0.00197	CcSEcCtD
Topotecan—Discomfort—Methotrexate—ankylosing spondylitis	0.000248	0.00197	CcSEcCtD
Topotecan—Constipation—Prednisone—ankylosing spondylitis	0.000246	0.00195	CcSEcCtD
Topotecan—Dizziness—Triamcinolone—ankylosing spondylitis	0.00024	0.00191	CcSEcCtD
Topotecan—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.00024	0.00191	CcSEcCtD
Topotecan—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00024	0.00191	CcSEcCtD
Topotecan—Infection—Methotrexate—ankylosing spondylitis	0.000239	0.0019	CcSEcCtD
Topotecan—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000237	0.00188	CcSEcCtD
Topotecan—Asthenia—Betamethasone—ankylosing spondylitis	0.000237	0.00188	CcSEcCtD
Topotecan—Asthenia—Dexamethasone—ankylosing spondylitis	0.000237	0.00188	CcSEcCtD
Topotecan—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000236	0.00187	CcSEcCtD
Topotecan—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000235	0.00187	CcSEcCtD
Topotecan—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000235	0.00187	CcSEcCtD
Topotecan—Nausea—Prednisolone—ankylosing spondylitis	0.000235	0.00187	CcSEcCtD
Topotecan—Pruritus—Dexamethasone—ankylosing spondylitis	0.000233	0.00185	CcSEcCtD
Topotecan—Pruritus—Betamethasone—ankylosing spondylitis	0.000233	0.00185	CcSEcCtD
Topotecan—Skin disorder—Methotrexate—ankylosing spondylitis	0.000233	0.00185	CcSEcCtD
Topotecan—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000232	0.00184	CcSEcCtD
Topotecan—Vomiting—Triamcinolone—ankylosing spondylitis	0.000231	0.00184	CcSEcCtD
Topotecan—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000231	0.00183	CcSEcCtD
Topotecan—Rash—Triamcinolone—ankylosing spondylitis	0.000229	0.00182	CcSEcCtD
Topotecan—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000229	0.00182	CcSEcCtD
Topotecan—Anorexia—Methotrexate—ankylosing spondylitis	0.000229	0.00182	CcSEcCtD
Topotecan—Rash—Methylprednisolone—ankylosing spondylitis	0.000229	0.00182	CcSEcCtD
Topotecan—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000229	0.00182	CcSEcCtD
Topotecan—Urticaria—Prednisone—ankylosing spondylitis	0.000228	0.00181	CcSEcCtD
Topotecan—Headache—Triamcinolone—ankylosing spondylitis	0.000228	0.00181	CcSEcCtD
Topotecan—Headache—Methylprednisolone—ankylosing spondylitis	0.000227	0.00181	CcSEcCtD
Topotecan—Abdominal pain—Prednisone—ankylosing spondylitis	0.000227	0.0018	CcSEcCtD
Topotecan—Body temperature increased—Prednisone—ankylosing spondylitis	0.000227	0.0018	CcSEcCtD
Topotecan—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000226	0.00179	CcSEcCtD
Topotecan—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000226	0.00179	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000219	0.00174	CcSEcCtD
Topotecan—Dizziness—Dexamethasone—ankylosing spondylitis	0.000218	0.00173	CcSEcCtD
Topotecan—Dizziness—Betamethasone—ankylosing spondylitis	0.000218	0.00173	CcSEcCtD
Topotecan—Nausea—Triamcinolone—ankylosing spondylitis	0.000216	0.00172	CcSEcCtD
Topotecan—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000216	0.00171	CcSEcCtD
Topotecan—Nausea—Methylprednisolone—ankylosing spondylitis	0.000216	0.00171	CcSEcCtD
Topotecan—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000214	0.0017	CcSEcCtD
Topotecan—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000212	0.00168	CcSEcCtD
Topotecan—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000211	0.00168	CcSEcCtD
Topotecan—Vomiting—Dexamethasone—ankylosing spondylitis	0.00021	0.00167	CcSEcCtD
Topotecan—Vomiting—Betamethasone—ankylosing spondylitis	0.00021	0.00167	CcSEcCtD
Topotecan—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000209	0.00166	CcSEcCtD
Topotecan—Rash—Dexamethasone—ankylosing spondylitis	0.000208	0.00165	CcSEcCtD
Topotecan—Rash—Betamethasone—ankylosing spondylitis	0.000208	0.00165	CcSEcCtD
Topotecan—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000208	0.00165	CcSEcCtD
Topotecan—Dermatitis—Betamethasone—ankylosing spondylitis	0.000208	0.00165	CcSEcCtD
Topotecan—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000207	0.00165	CcSEcCtD
Topotecan—Fatigue—Methotrexate—ankylosing spondylitis	0.000207	0.00164	CcSEcCtD
Topotecan—Headache—Dexamethasone—ankylosing spondylitis	0.000207	0.00164	CcSEcCtD
Topotecan—Headache—Betamethasone—ankylosing spondylitis	0.000207	0.00164	CcSEcCtD
Topotecan—Asthenia—Prednisone—ankylosing spondylitis	0.000206	0.00164	CcSEcCtD
Topotecan—Pain—Methotrexate—ankylosing spondylitis	0.000205	0.00163	CcSEcCtD
Topotecan—Pruritus—Prednisone—ankylosing spondylitis	0.000203	0.00161	CcSEcCtD
Topotecan—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.000198	0.00157	CcSEcCtD
Topotecan—Diarrhoea—Prednisone—ankylosing spondylitis	0.000197	0.00156	CcSEcCtD
Topotecan—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000196	0.00156	CcSEcCtD
Topotecan—Nausea—Dexamethasone—ankylosing spondylitis	0.000196	0.00156	CcSEcCtD
Topotecan—Nausea—Betamethasone—ankylosing spondylitis	0.000196	0.00156	CcSEcCtD
Topotecan—Urticaria—Methotrexate—ankylosing spondylitis	0.000191	0.00152	CcSEcCtD
Topotecan—Dizziness—Prednisone—ankylosing spondylitis	0.00019	0.00151	CcSEcCtD
Topotecan—Body temperature increased—Methotrexate—ankylosing spondylitis	0.00019	0.00151	CcSEcCtD
Topotecan—Abdominal pain—Methotrexate—ankylosing spondylitis	0.00019	0.00151	CcSEcCtD
Topotecan—Vomiting—Prednisone—ankylosing spondylitis	0.000183	0.00145	CcSEcCtD
Topotecan—Rash—Prednisone—ankylosing spondylitis	0.000181	0.00144	CcSEcCtD
Topotecan—Dermatitis—Prednisone—ankylosing spondylitis	0.000181	0.00144	CcSEcCtD
Topotecan—Headache—Prednisone—ankylosing spondylitis	0.00018	0.00143	CcSEcCtD
Topotecan—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000177	0.00141	CcSEcCtD
Topotecan—Asthenia—Methotrexate—ankylosing spondylitis	0.000172	0.00137	CcSEcCtD
Topotecan—Nausea—Prednisone—ankylosing spondylitis	0.000171	0.00136	CcSEcCtD
Topotecan—Pruritus—Methotrexate—ankylosing spondylitis	0.00017	0.00135	CcSEcCtD
Topotecan—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000164	0.00131	CcSEcCtD
Topotecan—Dizziness—Methotrexate—ankylosing spondylitis	0.000159	0.00126	CcSEcCtD
Topotecan—Vomiting—Methotrexate—ankylosing spondylitis	0.000153	0.00121	CcSEcCtD
Topotecan—Rash—Methotrexate—ankylosing spondylitis	0.000151	0.0012	CcSEcCtD
Topotecan—Dermatitis—Methotrexate—ankylosing spondylitis	0.000151	0.0012	CcSEcCtD
Topotecan—Headache—Methotrexate—ankylosing spondylitis	0.00015	0.0012	CcSEcCtD
Topotecan—Nausea—Methotrexate—ankylosing spondylitis	0.000143	0.00113	CcSEcCtD
